Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep1088 | Hot topics (including COVID-19) | ECE2020

Cushing’s disease recurrence during peripartum period: A case report

Fellipe Carvalho Viola Luiz , Muniz Raquel , Stefanello Lariana , Massucati Negri Maurício , Warszawski Leila

Introduction: Even with a high incidence of infertility owing to the suppressive effects of hypercortisolism in the gonadal axis, either associated or not to hyperandrogenism and ovulatory dysfunction, Cushing’s syndrome (CS) during pregnancy has been reported. This could be due to a greater rate of CS among women in reproductive age; however, it is a rare condition, with fewer than 200 cases reported in the literature. In general, CS affects 2–25 people to every 1...

ea0022h1.2 | Oral Communications Highlights 1 | ECE2010

Novel pathogenetic pathways of adrenocortical tumors revealed by meta-analysis of genomics data

Szabo Peter , Tamasi Viola , Andrasfalvy Marton , Patocs Attila , Toth Miklos , Falus Andras , Racz Karoly , Igaz Peter

Objective: Sporadic adrenocortical tumors are common, but their pathogenesis is poorly elucidated. Several mRNA profiling and comparative genome hybridization (CGH) studies have been performed on adrenocortical tumors to date. Meta-analysis of these results may be warranted due to the low number of tumor samples examined in several individual studies. Here, we present an integrative meta-analysis of gene expression microarray and CGH studies performed to date on sporadic adren...

ea0073aep880 | Late Breaking | ECE2021

Subacute thyroiditis at the time of SARS-CoV-2 pandemic

Brancatella Alessandro , Viola Nicola , Rutigliano Grazia , Daniele Sgrò , Santini Ferruccio , Latrofa Francesco

BackgroundSubacute thyroiditis (SAT) has been related to acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated the incidence and the severity of SAT due to SARS-CoV-2.MethodsA cross-sectional, retrospective study was conducted at the Endocrinology Unit of University-Hospital of Pisa, Italy. All patients experiencing SAT arisen within a period of 15 days earlier and yet untreated, assessed from J...

ea0092op-03-01 | Oral Session 3: Signalling in Thyroid cancer | ETA2023

Patient-Derived in vitro models for unraveling medullary thyroid cancer microenvironment and therapy resistance

Stellaria Grassi Elisa , Ghiandai Viola , Cirello Valentina , Gazzano Giacomo , Dionigi Gianlorenzo , Persani Luca , Fugazzola Laura

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor arising from parafollicular C-cells. Nowadays different targeted therapies are available, directed mostly against the main genetic driver of MTC, RET, and against the common pro-oncogenic pathways of VEGF, EGFR and c-MYC. Despite this, an escape phenomenon has been observed with sudden disease progression during treatment, leaving surgery as the only curative treatment. The evaluation of pre and post treatment ge...

ea0081p126 | Endocrine-Related Cancer | ECE2022

Ultrasound and cytological features of thyroid nodules with aggressive behavior: from histology to clinic

Sgro Daniele , Greco Giuseppe , Brancatella Alessandro , Viola Nicola , Casula Mauro , Torregrossa Liborio , Rago Teresa , Santini Ferruccio , Latrofa Francesco

Fine-Needle Aspiration Biopsy (FNAB) is the recommended diagnostic tool for differentiating malignant from benign thyroid nodules and provides indication for surgical decisions. According to the Italian system, thyroid nodules are classified as TIR 1/1C, TIR 2, TIR 3A, TIR3B, TIR4 or TIR5, which correspond to Thy I, Thy II, Thy III, Thy IV, Thy V and Thy VI categories of the Bethesda system. TIR 3 identifies the indeterminate nodules. Surgery is usually recommended for TIR 3B,...

ea0037ep370 | Diabetes (pathiophysiology & epitemiology) | ECE2015

Comparison between aldosterone and renin measurement by chemiluminescent immunoassay and RIA for the diagnosis of primary aldosteronism

Burrello Jacopo , Buffolo Fabrizio , Monticone Silvia , Williams Tracy Ann , Viola Andrea , Mengozzi Giulio , Veglio Franco , Mulatero Paolo

Objective: Primary aldosteronism (PA) is the most frequent cause of secondary hypertension. According to the Endocrine Society Guidelines, up to 50% of hypertensive patients should be screened for PA, using the aldosterone to renin (or plasma renin activity (PRA)) ratio (AARR and ARR respectively). The automated Diasorin LIAISON chemiluminescent immunoassay for renin and aldosterone measurement became available and in many laboratories is currently used instead of the classica...

ea0029p49 | Adrenal cortex | ICEECE2012

Prevalence and Characteristics of Familial Hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino - GENetic forms).

Mulatero P. , Tizzani D. , Viola A. , Monticone S. , Williams T. , Burrello J. , Galmozzi M. , Fulcheri C. , Chiarlo M. , Veglio F.

Primary Aldosteronism (PA) is the most frequent cause of secondary hypertension and patients display an increased prevalence of cardiovascular events compared to essential hypertensives. To date, three familial forms of PA have been described and termed, familial hyperaldosteronism types I, II and III (FH-I to -III). The aim of this study was to investigate the prevalence and clinical characteristics of the three forms of FH in a large population of PA patients. Three hundred ...

ea0081p464 | Thyroid | ECE2022

Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade

Brancatella Alessandro , Pierotti Laura , Lupi Isabella , Montanelli Lucia , Viola Nicola , Sgro Daniele , Sardella Chiara , Antonangeli Lucia , Brogioni Sandra , Cremolini Chiara , Marcocci Claudio , Santini Ferruccio , Latrofa Francesco

Objective: Destructive thyroiditis is the most common endocrine immune related adverse event (iRAEs) in patients treated with anti-PD1/PD-L1 agents. Given its self-limited course, current guidelines recommend no treatment for this iRAE. Nevertheless in patients with enlarged thyroid volume and a poor performance status, thyrotoxicosis may be particularly severe and harmful. Aim of the study is to evaluate if steroid treatment might be useful in improving thyrotoxicosis in subj...

ea0084ps2-09-83 | Thyroid Hormone ACTION | ETA2022

FAM83B is involved in thyroid cancer cell differentiation and migration

Cirello Valentina , Stellaria Grassi Elisa , Pogliaghi Gabriele , Ghiandai Viola , Ermellino Laura , Muzza Marina , Gazzano Giacomo , Persani Luca , Colombo Carla , Fugazzola Laura

FAM83B has been recently identified as an oncogene involved in the development and progression of several malignancies, but its role in thyroid cancers (TC) is still unclear. In the present study, we examined the expression of FAM83B and its possible involvement in cell migration and differentiation, in neoplastic and normal thyroid tissues and in TC human cell lines. We found that FAM83B expression in TC varies according to tumor histotype, being si...

ea0070aep332 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Immune checkpoint inhibitors (ICIs) and ‘Fulminant Diabetes’: Two emblematic cases

Sgro’ Daniele , Giannarelli Rosa , Aragona Michele , Viola Nicola , Cosentino Giada , Brancatella Alessandro , Latrofa Francesco , Del Prato Stefano , Santini Ferruccio , Marcocci Claudio , Lupi Isabella

Context: Programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) are key regulators in T-cell activation and tolerance. Nivolumab (PD-1 inhibitor) and Atezolizumab (PD-L1 inhibitor) are monoclonal antibodies approved for the treatment of several types of advanced cancers. Immune checkpoint inhibition caused by these drugs can result in immune-related adverse events (irAEs) New-onset diabetes mellitus has been reported in fewer than 1% of patients an...